GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zydus Lifesciences ZYDUSLIFE.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

1,215.90

+1.50%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Zydus Lifesciences

Its shares trade on NSE under the ticker ZYDUSLIFE.NS. It has been listed since 15 May 1995. In the fiscal year to 31 March 2026, it reported revenue of ₹271.48bn and net income of ₹50.40bn. At that date it held total assets of ₹524.07bn and shareholders' equity of ₹271.11bn.

Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The company is headquartered in Ahmedabad, Gujarat. The firm is focused on delivering care and nurturance for the patients, backed by science and cutting-edge technology. The firm has a pipeline for Biologics and Vaccines. The firm offers Lipaglyn to treat diabetic dyslipidemia. The company offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The firm in collaboration with Medicines for Malaria Venture (MMV) is developing ZY19489, a single dose cure for Malaria. The Company’s novel oral small molecule, ZYIL1, is an NLRP3 inhibitor candidate. Its ZyCoV-D is a plasmid Deoxyribonucleic acid (DNA) Vaccine for human use. The firm provides Twinrab, which is a novel biological entity for rabies post-exposure prophylaxis. The firm has operations globally and is present in approximately 55 countries worldwide, with 36 manufacturing plants and eight research and development centers.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
15 May 1995
Employees
23,743

Leadership

Pay as last reported

  • Shri. Pankaj PatelNon-Executive Chairman of the Board, since 2017₹1.2m
  • Mr. Nitin ParekhChief Financial Officer₹54.3m
  • Mr. Dhaval SoniCompany Secretary, Compliance Officer₹2.1m
  • Dr. Sharvil PatelManaging Director, Executive Director, since 1997₹300.0m
  • Mr. Ganesh NayakExecutive Director, since 2017₹140.0m
  • Mr. Mukesh PatelNon-Executive Director₹4.0m
  • Shri. Apurva DiwanjiNon-Executive Independent Director₹4.0m
  • Ms. Upasana KonidelaNon-Executive Independent Director₹3.5m
  • Mr. Akhil MonappaNon-Executive Independent Director₹3.5m
  • Ms. Shelina ParikhNon-Executive Independent Director
  • Shri. Bhadresh ShahNon-Executive Independent Director₹4.1m
  • Mr. Arvind BothraHead - Investor Relations, since 2022

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
74
Environment
83
Social
83
Governance
55
Direct emissions (scope 1)
67,705.11 t
Energy emissions (scope 2)
239,708.53 t
Value chain emissions (scope 3)
24,393 t
Women in the workforce
7.56%
Carbon reduction policy
Yes
Human rights policy
Yes

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.